

EMA/580025/2016

European Medicines Agency decision

P/0237/2016

of 9 September 2016

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for elafibranor (EMEA-001857-PIP01-15) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0237/2016

of 9 September 2016

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for elafibranor (EMA-001857-PIP01-15) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Genfit SA on 7 September 2015 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 22 July 2016, in accordance with Article 18 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for elafibranor, capsule, hard, coated tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for elafibranor, capsule, hard, coated tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for elafibranor, capsule, hard, coated tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Genfit SA, 885 avenue Eugène Avinée, 59120 – Loos, France.

EMA/PDCO/231683/2016

London, 22 July 2016

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-001857-PIP01-15

Scope of the application

Active substance(s):

Elafibranor

Condition(s):

Treatment of non-alcoholic fatty liver disease (NAFLD) including non-alcoholic steatohepatitis (NASH)

Pharmaceutical form(s):

Capsule, hard

Coated tablet

Route(s) of administration:

Oral use

Name / corporate name of the PIP applicant:

Genfit SA

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Genfit SA submitted for agreement to the European Medicines Agency on 7 September 2015 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 13 October 2015.

Supplementary information was provided by the applicant on 2 May 2016. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of non-alcoholic fatty liver disease (NAFLD) including non-alcoholic steatohepatitis (NASH)

The waiver applies to:

- the paediatric population from birth to less than 2 years;
- capsule, hard, coated tablet, oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment of non-alcoholic fatty liver disease (NAFLD) including non-alcoholic steatohepatitis (NASH)

2.1.1. Indication(s) targeted by the PIP

Treatment of non-alcoholic fatty liver disease (NAFLD) including non-alcoholic steatohepatitis (NASH)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Capsule, hard

Coated tablet

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Study 1 Development of an age appropriate formulation
Non-clinical studies	1	Study 2 Definitive juvenile toxicity study in rats
Clinical studies	4	Study 3 Pharmacokinetic (PK)/pharmacodynamic (PD) study in children and adolescents 8 to less than 18

Area	Number of measures	Description
		years of age with NAFLD Study 4 Double-blind, placebo controlled efficacy and safety study in children and adolescents 8 to less than 18 years of age with NAFLD Study 5 Pharmacokinetic (PK)/pharmacodynamic (PD) study in children 2 to less than 8 years of age with NAFLD Study 6 Double-blind, placebo controlled efficacy and safety study in children 2 to less than 8 years of age with NAFLD
Extrapolation, modelling and simulation studies	1	Study 7 Modelling and simulation study to evaluate the use of the product in the treatment of children from 2 to less than 18 years of age with NAFLD
Other studies	1	Study 8 Review of NAFLD/NASH natural history studies
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By December 2025
Deferral for one or more measures contained in the paediatric investigation plan:	Yes